ESPR241220P2500
- 0.20
- +0.03+17.65%
Esperion Therapeutics Newsroom
Express News | Esperion Therapeutics Inc - No Serious Adverse Events Observed in Bempedoic Acid Trial
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...
US Manufacturing Index Rises To 43, Highest Since 2020
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Express News | Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Esperion Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Reporting Better-than-expected Q3 Financing Results Yesterday. Also, HC Wainwright & Co. Reiterated a Buy Rating on the Stock.
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16
Esperion Therapeutics | 10-Q: Q3 2024 Earnings Report
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Esperion Therapeutics | 8-K: Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Esperion Therapeutics Cash and Cash Equivalents Totaled $144.7M at Sept 30 >ESPR
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q3 Revenue $51.6M
Esperion Therapeutics Gives Mixed Q3 Results
Express News | Esperion Therapeutics Q3 Basic EPS USD -0.15